Longbio Pharma advanced LP-003 in seasonal allergic rhinitis after reporting that the candidate met the primary endpoint of total nasal symptom scores during peak pollen season in a phase 3 study. The update lands shortly after the company’s IPO on the Hong Kong Stock Exchange earlier this month, reinforcing momentum in allergy pipeline execution following the financing window.